Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world safety and effectiveness of insulin glargine 300 U/mL in participants with type 2 diabetes who fast during Ramadan: The observational ORION study.
Hassanein M, Buyukbese MA, Malek R, Pilorget V, Naqvi M, Berthou B, Shaltout I, Kumar Sahay R. Hassanein M, et al. Among authors: pilorget v. Diabetes Res Clin Pract. 2020 Aug;166:108189. doi: 10.1016/j.diabres.2020.108189. Epub 2020 May 1. Diabetes Res Clin Pract. 2020. PMID: 32360709 Free article.
[No title available]
[No authors listed] [No authors listed] PMID: 35730004
Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus.
Freemantle N, Mauricio D, Giaccari A, Bailey T, Roussel R, Franco D, Berthou B, Pilorget V, Westerbacka J, Bosnyak Z, Bonnemaire M, Cali AMG, Nguyên-Pascal ML, Penfornis A, Perez-Maraver M, Seufert J, Sullivan SD, Wilding J, Wysham C, Davies M. Freemantle N, et al. Among authors: pilorget v. Curr Med Res Opin. 2020 Apr;36(4):571-581. doi: 10.1080/03007995.2019.1708287. Epub 2020 Jan 19. Curr Med Res Opin. 2020. PMID: 31865758 Free article. Clinical Trial.
Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents.
Home PD, Dain MP, Freemantle N, Kawamori R, Pfohl M, Brette S, Pilorget V, Scherbaum WA, Vespasiani G, Vincent M, Balkau B. Home PD, et al. Among authors: pilorget v. Diabetes Res Clin Pract. 2015 May;108(2):350-9. doi: 10.1016/j.diabres.2015.01.030. Epub 2015 Jan 23. Diabetes Res Clin Pract. 2015. PMID: 25825361 Free article.
Insulin regimens and glycemic control in different parts of Europe over 4years after starting insulin in people with type 2 diabetes: Data from the CREDIT non-interventional study.
Blonde L, Marre M, Vincent M, Brette S, Pilorget V, Danchin N, Vespasiani G, Home P. Blonde L, et al. Among authors: pilorget v. Diabetes Res Clin Pract. 2017 Nov;133:150-158. doi: 10.1016/j.diabres.2017.08.016. Epub 2017 Aug 31. Diabetes Res Clin Pract. 2017. PMID: 28938142 Free article.
Insulin glargine compared with premixed insulin for management of insulin-naïve type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the open-label, randomized GALAPAGOS study.
Aschner P, Sethi B, Gomez-Peralta F, Landgraf W, Loizeau V, Dain MP, Pilorget V, Comlekci A. Aschner P, et al. Among authors: pilorget v. J Diabetes Complications. 2015 Aug;29(6):838-45. doi: 10.1016/j.jdiacomp.2015.04.003. Epub 2015 Apr 11. J Diabetes Complications. 2015. PMID: 25981123 Free article. Clinical Trial.
24 results